Clinical trials: Pulmonary Artery Hypertension
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension
Reverse Remodeling of the Pulmonary Vasculature: a Longitudinal, Investigational Study of the Effects of Sotatercept.
The goal of this study is to learn more about how sotatercept works and if it helps the lung arteries become healthier. Sotatercept will be associated with the following: 1.
- Trial name
- NCT07487441
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Franz Rischard, DO
Congenital Heart Disease, Pulmonary Arterial Hypertension
Efficacy of Triple-Combination Therapy in Severe PAH-CHD
Congenital heart disease (CHD) is a leading cause of pulmonary arterial hypertension (PAH) worldwide. Treatment for PAH associated with CHD (PAH-CHD) depends on the defect's type, size, and hemodynamic impact.
- Trial name
- NCT06196801
- Testing
- Triple-combination therapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Guangdong Provincial People's Hospital
Pulmonary Arterial Hypertension PAH
Implementing the Wuqinxi on Patients With Pulmonary Arterial Hypertension
Aims and objective: The primary objective of this study was to assess the effects of a traditional Chinese Qigong practice known as Wuqinxi on activity tolerance，negative emotions and quality of life in pulmonary arterial…
- Trial name
- PAH (NCT06454422)
- Testing
- wu qinxi
- Volunteers
- 60 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University
Pulmonary Arterial Hypertension
Riociguat in Triple Therapy for Pulmonary Arterial Hypertension in Real-World Practice
Pulmonary arterial hypertension is a rare and serious disease that can lead to heart failure and early death despite modern treatments.
- Trial name
- REAPPRAISED (NCT07374302)
- Volunteers
- 15 people
- Sponsor
- Caio Júlio César dos Santos Fernandes
Pulmonary Arterial Hypertension, Dilated Cardiomyopathy
IntelliStent for Pulmonary Flow Adjustment in Congenital Heart Disease and Dilated Cardiomyopathy
IntelliStent is intended to achieve reduction of pulmonary hypertension, improvements in symptoms and quality of life in pediatric, adolescent and adult patients with congenital heart disease associated pulmonary arterial…
- Conditions
- Pulmonary Arterial Hypertension, Dilated Cardiomyopathy, Congenital Heart Disease
- Trial name
- HEARTFUL-CHD (NCT06072937)
- Testing
- IntelliStent
- Volunteers
- 10 people
- Sponsor
- HeartPoint Global
Right Heart Failure, Pulmonary Hypertension
Body Volume Regulation in Pulmonary Arterial Hypertension With Right Ventricular Failure
Secondary hyperaldosteronism and the non-osmotic release of arginine vasopressin (AVP) are the major factors in sodium and water retention in pulmonary arterial hypertension with right ventricular failure.
- Trial name
- NCT00811486
- Testing
- Spironolactone and conivaptan
- Where
- United States
- Sponsor
- University of Colorado, Denver
Pulmonary Hypertension
Platelet Reactivity and Treatment With Prostacyclin Analogues in Pulmonary Arterial Hypertension
Background: Prostacyclin analogues (epoprostenol, treprostinil and iloprost) induce vasodilation in advanced pulmonary arterial hypertension (PAH) but also inhibit platelets, increasing patients' bleeding risk.
- Trial name
- PAPAYA (NCT04578223)
- Where
- Poland
- Volunteers
- 80 people
- Sponsor
- Medical University of Warsaw
Pulmonary Hypertension
RUS-registry of PH
Russian National Registry of Patients With Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a multicenter, observational study of the clinical course and disease management of PAH…
- Trial name
- NCT03707561
- Testing
- Right Heart Catheterization (RHC)
- Volunteers
- 200 people
- Sponsor
- Russian Cardiology Research and Production Center
Pulmonary Arterial Hypertension
A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that carry blood from the heart to the lungs. PAH occurs when the openings in the blood vessels of the lungs get smaller and smaller.
- Trial name
- ROAR (NCT04813926)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 50 sites in United States, Puerto Rico
- Volunteers
- 500 people
- Sponsor
- Bayer
Pulmonary Hypertension
Integrated Diagnostics Characterization of Right Ventricular Diastolic Flow Dynamics in Pulmonary Arterial Hypertension
Pulmonary hypertension (PH) is a condition in which high blood pressure develops in the lungs and right side of the heart. People with PH suffer from shortness of breath, chest pain, heart failure, heart rhythm problems, and…
- Trial name
- NCT01491646
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- National Jewish Health
Pulmonary Arterial Hypertension (PAH)
Efficacy and Safety of Treprostinil in Intermediate-Risk Pulmonary Arterial Hypertension
Pulmonary Arterial Hypertension (PAH) is a serious condition that puts strain on the right side of the heart. While oral medications can help, many patients with intermediate-risk PAH may not see enough improvement, and their…
- Trial name
- NCT07177703
- Testing
- Treprostinil
- Volunteers
- 32 people
- Sponsor
- Shanghai Zhongshan Hospital
Obstructive Sleep Apnea (OSA), Pulmonary Hypertension
Echocardiographic Assessment of Pulmonary Hypertension in Obstructive Sleep Apnea
This study investigates the association between obstructive sleep apnea (OSA) and pulmonary hypertension (PH), focusing on the relationship between OSA severity and pulmonary arterial pressures in adult patients.
- Trial name
- NCT07184060
- Volunteers
- 55 people
- Sponsor
- Assiut University
Pulmonary Arterial Hypertension
Tyvaso Dosing and Titration Evaluation: TyTRATE Registry
This prospective, observational, multi-center, patient registry will follow patients who are newly initiated on Tyvaso for the treatment of Pulmonary Arterial Hypertension (PAH).
- Trial name
- NCT01799473
- Where
- 52 sites in United States, Puerto Rico
- Volunteers
- 98 people
- Sponsor
- United Therapeutics
Pulmonary Arterial Hypertension (PAH)
Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to compare the efficacy, safety, and tolerability of tiprelestat plus Standard of Care (SOC) compared with placebo plus SOC in patients with World Health Organization (WHO) functional class…
- Trial name
- ATHENA (NCT07601295)
- Testing
- Tiprelestat (5 mg), Tiprelestat (10 mg)
- Where
- 10 sites in United States
- Volunteers
- 90 people
- Sponsor
- Stanford University
Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease
Sleep-Assessment in Patients Between High Altitude HA vs. Sea Level LA in Patients With Pulmonary Arterial Hypertension PAH
To study the effect of relocation from high altitude (Quito Ecuador: 2850m) to sea level on sleeping parameters by polygraphy in patients with pulmonary arterial hypertension PAH, who live permanently >2600m.
- Conditions
- Pulmonary Arterial Hypertension (PAH), Pulmonary Vascular Disease, Polygraphy, Sleep
- Trial name
- NCT07801963
- Testing
- Descent to sea level
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- Silvia Ulrich Somaini
Comorbidities and Coexisting Conditions, Alzheimer Disease
An Integrated Solution for Sustainable Care for Multimorbid Elderly Patients With Dementia
The CAREPATH will conduct Technical Validation and Usability (TVU) study by involving ≥ 45 target end users (16 patients with MCI or mild dementia with their informal caregivers and 16 healthcare professionals from various…
- Conditions
- Comorbidities and Coexisting Conditions, Alzheimer Disease, Dementia, Malnutrition
- Trial name
- CAREPATH (NCT05104593)
- Testing
- Intervention tested (CAREPATH)
- Where
- Spain
- Volunteers
- 204 people
- Sponsor
- Complejo Hospitalario Universitario de Albacete
Congenital Heart Disease, Pulmonary Arterial Hypertension
4DFlow Magnetic Resonance Imaging in Patients With Pulmonary Hypertension Associated With Congenital Heart Disease
Congenital heart disease is the most common congenital anomaly. The life expectancy of children with congenital heart disease has increased considerably in recent years.
- Trial name
- 4DFlowHTAPCC (NCT03928002)
- Testing
- 4D Flow magnetic resonance imagery, Cardiac catheterization
- Where
- France
- Volunteers
- 50 people
- Sponsor
- Centre Chirurgical Marie Lannelongue
Pulmonary Arterial Hypertension
Revatio Special Investigation for Long-term Use in Pediatric Patients
Secondary data collection study: safety and effectiveness of Revatio in pediatric patients under Japanese medical practice
- Trial name
- NCT03364244
- Testing
- Sildenafil
- Where
- Japan
- Volunteers
- 1,023 people
- Sponsor
- Viatris Pharmaceuticals Japan Inc
Idiopathic Pulmonary Arterial Hypertension
The Study of Apelin-APJ System on Pulmonary Hypertension Patients and Healthy Subjects
The purpose of this study is to Determine blood peptide levels and investigate any tissue gradients of apelin in patients with idiopathic pulmonary arterial hypertension and healthy volunteers.
- Trial name
- EXAP (NCT01590108)
- Testing
- (Pyr1)apelin-13, Saline
- Where
- 2 sites in United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Pulmonary Arterial Hypertension
A Study to Observe the Safety, Tolerability, and Efficacy of Remodulin
This is a multi-center, single-arm, prospective study to enroll patients diagnosed as pulmonary arterial hypertension. The objective in this study is to observe the efficacy and safety of treprostinil in subjects with pulmonary…
- Trial name
- NCT06603285
- Testing
- Treprostinil
- Volunteers
- 20 people
- Sponsor
- Excelsior